Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme’s Renvela Approved For Kidney Disease Patients On Dialysis

This article was originally published in The Pink Sheet Daily

Executive Summary

Filing for predialysis indication is on track for first half of 2008 after “positive” outcome of FDA Cardio-Renal Advisory Committee meeting, Genzyme Renal President Butler tells “The Pink Sheet” DAILY.

You may also be interested in...



Genzyme: Next-Generation Sevelamer Bound For Clinic Next Year

Enzyme-replacement sales strong as firm builds on renal franchise.

Genzyme: Next-Generation Sevelamer Bound For Clinic Next Year

Enzyme-replacement sales strong as firm builds on renal franchise.

Advisory Committee Rejects Surrogate Endpoint For Phosphate Binders

Sponsors are seeking to expand the indication of the CKD therapies without clinical data.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065238

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel